Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
University Library
Adelaide Festival of Ideas
Barr Smith Press
Friends of the University of Adelaide Library
Library Publications
Internal documents (Library staff only)
Library images
Library reports and papers
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 31-40 of 52 (Search time: 0.002 seconds).
previous
1
2
3
4
5
6
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?
Fitter, S.
;
Vandyke, K.
;
Schultz, C.
;
White, D.
;
Hughes, T.
;
Zannettino, A.
2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, H.
;
Giles, F.
;
Bhalla, K.
;
Pinilla-Ibarz, J.
;
Larson, R.
;
Gattermann, N.
;
Ottmann, O.
;
Hochhaus, A.
;
Radich, J.
;
Saglio, G.
;
Hughes, T.
;
Martinelli, G.
;
Kim, D.
;
Shou, Y.
;
Gallagher, N.
;
Blakesley, R.
;
Baccarani, M.
;
Cortes, J.
;
le Coutre, P.
2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy
Parker, W.
;
Lawrence, R.
;
Ho, M.
;
Irwin, D.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response
White, D.
;
Hughes, T.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
Parker, W.
;
Ho, M.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib
Branford, S.
;
Kim, D.
;
Soverini, S.
;
Haque, A.
;
Shou, Y.
;
Woodman, R.
;
Kantarjian, H.
;
Martinelli, G.
;
Radich, J.
;
Saglio, G.
;
Hochhaus, A.
;
Hughes, T.
;
Muller, M.
2013
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects
Vandyke, K.
;
Fitter, S.
;
Drew, J.
;
Fukumoto, S.
;
Schultz, C.
;
Sims, N.
;
Yeung, D.
;
Hughes, T.
;
Zannettino, A.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2010
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib
White, D.
;
Dang, P.
;
Engler, J.
;
Frede, A.
;
Osborn, M.
;
Saunders, V.
;
Manley, P.
;
Zrim, S.
;
Hughes, T.
Discover
Author
25
White, D.
14
Branford, S.
12
Hochhaus, A.
10
Kantarjian, H.
9
Saglio, G.
8
Kim, D.
8
Radich, J.
7
Larson, R.
7
Yeung, D.
6
Saunders, V.
.
next >
Subject
39
Pyrimidines
38
Leukemia, Myelogenous, Chronic, B...
33
Imatinib Mesylate
31
Piperazines
30
Benzamides
28
Antineoplastic Agents
27
Protein Kinase Inhibitors
19
Fusion Proteins, bcr-abl
15
Female
15
Male
.
next >
Date issued
2
2018
4
2017
2
2016
1
2015
3
2014
13
2013
7
2012
8
2011
12
2010